Introduction: Tirzepatide, a dual GIP and GLP-1 receptor agonist with ~98% purity and a five-day half-life, improves glycemic control and weight loss in type 2 diabetes patients. Ignoring the progression of type 2 https://innopeptides.com/collections/peptides